Table of Contents Author Guidelines Submit a Manuscript
Sarcoma
Volume 2007, Article ID 82012, 5 pages
http://dx.doi.org/10.1155/2007/82012
Case Report

Tumour Lysis Syndrome Occurring in a Patient with Metastatic Gastrointestinal Stromal Tumour Treated with Glivec (Imatinib Mesylate, Gleevec, STI571)

1Department of Surgery, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK
2Department of Pathology, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK
3Department of Oncology, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK

Received 30 November 2006; Revised 7 April 2007; Accepted 15 June 2007

Academic Editor: Penella Woll

Copyright © 2007 Elizabeth M. Pinder et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Rosai, “GIST: an update,” International Journal of Surgical Pathology, vol. 11, no. 3, pp. 177–186, 2003. View at Publisher · View at Google Scholar
  2. F. Duffaud and J.-Y. Blay, “Gastrointestinal stromal tumors: biology and treatment,” Oncology, vol. 65, no. 3, pp. 187–197, 2003. View at Publisher · View at Google Scholar
  3. R. P. Dematteo, M. C. Heinrich, W. M. El-Rifai, and G. Demetri, “Clinical management of gastrointestinal stromal tumors: before and after STI-571,” Human Pathology, vol. 33, no. 5, pp. 466–477, 2002. View at Publisher · View at Google Scholar
  4. A. T. van Oosterom, I. Judson, J. Verweij et al., “Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study,” The Lancet, vol. 358, no. 9291, pp. 1421–1423, 2001. View at Publisher · View at Google Scholar
  5. H. Joensuu, P. J. Roberts, M. Sarlomo-Rikala et al., “Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor,” New England Journal of Medicine, vol. 344, no. 14, pp. 1052–1056, 2001. View at Publisher · View at Google Scholar
  6. L. Baeksgaard and J. B. Sørensen, “Acute tumor lysis syndrome in solid tumors—a case report and review of the literature,” Cancer Chemotherapy and Pharmacology, vol. 51, no. 3, pp. 187–192, 2003. View at Publisher · View at Google Scholar
  7. R. P. DeMatteo, J. J. Lewis, D. Leung, S. S. Mudan, J. M. Woodruff, and M. F. Brennan, “Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival,” Annals of Surgery, vol. 231, no. 1, pp. 51–58, 2000. View at Publisher · View at Google Scholar
  8. M. H. Shiu, G. H. Farr, D. N. Papachristou, and S. I. Hajdu, “Myosarcomas of the stomach: natural history, prognostic factors and management,” Cancer, vol. 49, no. 1, pp. 177–187, 1982. View at Publisher · View at Google Scholar
  9. A. Vora, M. Bhutani, A. Sharma, and V. Raina, “Severe tumor lysis syndrome during treatment with STI 571 in a patient with chronic myelogenous leukemia accelerated phase,” Annals of Oncology, vol. 13, no. 11, pp. 1833–1834, 2002. View at Publisher · View at Google Scholar
  10. M. S. Cairo and M. Bishop, “Tumour lysis syndrome: new therapeutic strategies and classification,” British Journal of Haematology, vol. 127, no. 1, pp. 3–11, 2004. View at Publisher · View at Google Scholar
  11. S. Sallan, “Management of acute tumor lysis syndrome,” Seminars in Oncology, vol. 28, no. 2, supplement 5, pp. 9–12, 2001. View at Publisher · View at Google Scholar
  12. R. V. Smalley, A. Guaspari, S. Haase-Statz, S. A. Anderson, D. Cederberg, and J. A. Hohneker, “Allopurinol: intravenous use for prevention and treatment of hyperuricaemia,” Journal of Clinical Oncology, vol. 18, no. 8, pp. 1758–1763, 2000. View at Google Scholar
  13. P. R. Band, D. S. Silverberg, J. F. Henderson et al., “Xanthine nephropathy in a patient with lymphosarcoma treated with allopurinol,” New England Journal of Medicine, vol. 283, no. 7, pp. 354–357, 1970. View at Google Scholar
  14. S. C. Goldman, J. S. Holcenberg, J. Z. Finklestein et al., “A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis,” Blood, vol. 97, no. 10, pp. 2998–3003, 2001. View at Publisher · View at Google Scholar